Draft legislation details European Union (EU) plans to cut back its COVID-19 vaccine exports; the Biden administration announces a 3-month extension to Affordable Care Act (ACA) open enrollment; Johnson & Johnson (J&J) may not meet its March 31 vaccine delivery deadline.
Despite facing a third COVID-19 surge, the European Union has drafted legislation that will cut back its export of COVID-19 vaccines manufactured among member countries for 6 weeks, The New York Times reported. The 3 vaccines approved in the European Union—Pfizer/BioNTech, Moderna, and AstraZeneca—could all be affected, with AstraZeneca reportedly being the main target following its decision in January to reduce its vaccine supply by more than half. Meanwhile, the legislation also proposes blocking shipments to countries with higher vaccination rates than the European Union.
Following its previous announcement of a February 15 to May 15 special open enrollment period for HealthCare.gov marketplace plans among the 36 states that have expanded Medicaid coverage, the Biden administration is extending enrollment through August 15, The Hill reported. Current plan enrollees will be allowed to continue to change their plans, although doing so could reset their cost-sharing limits to $0, meaning more out-of-pocket expenses. In the first 2 weeks alone of the original extension, more than 200,000 Americans enrolled in plans.
Having promised to deliver 20 million doses of its single-shot COVID-19 vaccine to the federal government by month’s end, early numbers are showing Johnson & Johnson (J&J) may fall short of meeting this goal, according to Politico. Only 20%, or 4 million doses, have reportedly been delivered to the government thus far, while 4.6 million have been distributed to states and federal vaccine programs. The news follows an Emergency Use Authorization from the FDA that will permit a Catalent Pharma plant in Bloomington, Indiana, to produce and ship vaccines for J&J.
Study Highlights BMP7 As a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More